Danske Bank A/S
Change company Symbol lookup
Select an option...
DNKEY Danske Bank A/S
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
MMM 3M Co
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
Go

Financials : Banks | Mid Cap Value
Based in Denmark
Company profile

Danske Bank A/S is engaged in providing payment services, trading in securities and other instruments, depositing of surplus liquidity and provision of short- and long-term financing. Its segments include Personal Banking, Business Banking, Corporates & Institutions, Wealth Management, Northern Ireland, Non-core and Other Activities. The Personal Banking segment provides personal advice that addresses its customers' individual needs. The Business Banking segment offers solutions within financing, investing, cash management and risk management. The Corporates & Institutions segment provides strategic advice, financial solutions and products. The Wealth Management segment offers a range of products and services within pension savings and wealth and asset management. The Northern Ireland segment serves personal and business customers. The Non-core segment consists of loans to customers in Ireland. The Bank's Other Activities include its treasury and support functions.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$7.60
Day's Change
0.0901 (1.20%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.60
Day's Low
7.58
Volume
(Light)

Today's volume of 1,706 shares is on pace to be much lighter than DNKEY's 10-day average volume of 15,080 shares.

1,706

Berger Montague Class action lawsuit: Big Pharma firm Gilead Sciences sent envelopes marking recipients as users of HIV medication

2:22 pm ET May 22, 2020 (PR Newswire) Print

An Alabama man was mortified when an envelope for him with the return address HIV Prevention Team in bold red lettering turned up in his workplace mailroom. An Indiana man, who is so protective of his confidentiality that he fills his HIV-related prescriptions at a different pharmacy chain from where he gets his other medications, was shocked to receive the same mailing.

The two men are plaintiffs in a federal class action lawsuit filed last night in the U.S. District Court for the Northern District of California, alleging that the California pharmaceutical company Gilead Sciences Inc. illegally compromised the privacy rights of people taking its medications by recklessly mailing the inappropriately marked envelopes after promising its customers confidentiality. The exact number of Gilead customers who received the mailing is not immediately known.

https://mma.prnewswire.com/media/1172114/Berger_Montague_AIDS_Law_Project.jpg

https://mma.prnewswire.com/media/1172115/Berger_Montague_Langer_Grogan_Diver.jpg

https://mma.prnewswire.com/media/1172080/Berger_Montague_Gilead_Letter.jpg

The plaintiffs from Alabama and Indiana, who do not know each other and who are listed with pseudonyms to protect their confidentiality, retained a litigation team of Ronda B. Goldfein of the AIDS Law Project of Pennsylvania, Shanon J. Carson of Berger Montague PC, and John J. Grogan of Langer Grogan & Diver P.C.

The case is similar to a federal class action lawsuit filed three years ago by Goldfein and Carson against the insurance company Aetna after more than 12,000 customers received large-windowed envelopes revealing they had prescriptions for HIV medications. Aetna settled that case for more than $17 million.

Gilead is a biopharmaceutical company headquartered in Foster City, Calif., that develops and sells prescription drugs, including for the treatment and prevention of HIV. They include Truvada and Descovy, the only drugs available for the prescribed medication regimen known as pre-exposure prophylaxis ("PrEP"), for people who want to avoid contracting HIV. The plaintiffs in the lawsuit are participants in Gilead's Advancing Access Program, a patient-assistance program offering discounts on the expensive PrEP drugs.

In signing up for the Advancing Access Program, Gilead customers were promised confidentiality and did not expect or agree to receive mail from Gilead that would link them to HIV. Stigma surrounding HIV can lead to discrimination in employment, housing, education, and health care, and even violence. Fear of that stigma is widely recognized as contributing to the AIDS epidemic by discouraging people from getting tested. To ensure that people feel safe to come forward to be tested and treated for HIV, many states have adopted laws that protect the confidentiality of HIV-related information and provide for statutory damages. The lawsuit demands that Gilead reform its mailing procedures and pay monetary damages to the plaintiffs and class members.

"The Aetna case put a spotlight on the obligation to safeguard confidential HIV information," said Goldfein. "We hoped that the Aetna case would put an end to faulty mailings by companies holding this sensitive information. Mail delivery should not strike fear in the hearts of people who live with HIV or are at risk of getting it."

Carson said: "Our law firm is constantly battling on behalf of our clients in cases involving serious data breaches and violations of consumers' privacy rights. Ironically, while many of these cases involve consumer data stolen by third parties, the violation of privacy rights in this case is wholly self-inflicted by Gilead. Indeed, our clients report that when they called Gilead to complain about the above mailing at issue, the company acknowledged responsibility. Now we ask that Gilead, like Aetna before it, step up to the plate and pay plaintiffs and class members the damages they are owed. We look forward to litigating this case in court and obtaining a fair and just resolution for our clients."

Those affected by Gilead Sciences' privacy breach should contact the AIDS Law Project of Pennsylvania at 215-587-9377 or by using the contact information below. Additional information about this lawsuit is available at www.aidslawpa.org and www.bergermontague.com/gilead.

Founded in 1988, the AIDS Law Project of Pennsylvania is the nation's only independent nonprofit public-interest law firm providing free legal services to people living with HIV and those affected by the epidemic.

Berger Montague PC, a national plaintiffs' law firm, is headquartered in Philadelphia and has offices in San Diego, Minneapolis, and Washington, D.C. The firm has played lead roles in major cases for 50 years, resulting in recoveries of more than $36 billion for its clients and the class members they have represented.

Langer Grogan & Diver P.C. is a Philadelphia-based complex commercial litigation boutique law firm built on a focus and dedication to the public good.

FOR MORE INFORMATION, CONTACT:

Ronda B. Goldfein                Shanon J. Carson
Executive Director               Managing Shareholder
AIDS Law Project of Pennsylvania Berger Montague PC
Email: goldfein@aidslawpa.org    Email: scarson@bm.net
Telephone:(215) 680-1305         Telephone: (215) 875-4656
John J. Grogan
Partner
Langer Grogan & Diver P.C.
Email: jgrogan@langergrogan.com
Telephone: (215) 320-5662

https://mma.prnewswire.com/media/232479/berger_montague.jpg

https://c212.net/c/img/favicon.png?sn=DC15623&sd=2020-05-22

View original content to download multimedia:http://www.prnewswire.com/news-releases/berger-montague-class-action-lawsuit-big-pharma-firm-gilead-sciences-sent-envelopes-marking-recipients-as-users-of-hiv-medication-301064420.html

SOURCE Berger Montague

https://rt.prnewswire.com/rt.gif?NewsItemId=DC15623&Transmission_Id=202005221422PR_NEWS_USPR_____DC15623&DateId=20200522

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.